Fourth and final issue of GaBI Journal’s 10th volume

2021 ◽  
Vol 10 (4) ◽  
pp. 151-151
Author(s):  
Philip D Walson
Keyword(s):  
Veterinary Pharmaceuticals ◽  
Pharmaceutical Expenditures

This issue of the GaBI Journal contains only a limited number of articles, but these include two scientifi c very data-rich articles and an interesting and important expose on the use and misuse of products to treat COVID-19 patients. All three articles have potentially major implications for the global struggle to deal with the current COVID-19 pandemic; either with respect to the proper use of biosimilar products to safely reduce COVID-19 related and non-related pharmaceutical expenditures, as well as to the effects of the pandemic on the criminal use and abuse of human and veterinary pharmaceuticals and other products, e.g. disinfectants.

scholarly journals Determinants of pharmaceutical expenditures of urban households: A time series study in Kermanshah province (Iran)

10.19082/1470 ◽  
2015 ◽  
Vol 7 (7) ◽  
pp. 1470-1475 ◽  
Author(s):  
Behzad Karami Matin ◽  
Saeed Reza Azami ◽  
Saeid Mahmoudi ◽  
Satar Rezaei ◽  
Faramarz Shaahmadi ◽  
...  
Keyword(s):  
Time Series ◽  
Urban Households ◽  
Time Series Study ◽  
Pharmaceutical Expenditures ◽  
Series Study

Comparison of Four Extraction Methods for the Determination of Veterinary Pharmaceuticals in Sediment

2016 ◽  
Vol 79 (3-4) ◽  
pp. 209-223 ◽  
Author(s):  
D. Drljača ◽  
Danijela Ašperger ◽  
M. Ferenčak ◽  
M. Gavranić ◽  
S. Babić ◽  
...  
Keyword(s):  
Extraction Methods ◽  
Veterinary Pharmaceuticals

Paying the right price for pharmaceuticals: a case study of why the comparator matters

2011 ◽  
Vol 35 (3) ◽  
pp. 267 ◽  
Author(s):  
Jean M. Spinks ◽  
Jeff R. J. Richardson
Keyword(s):  
Optimal Pricing ◽  
Regulatory Capture ◽  
Pharmaceutical Pricing ◽  
Pricing Policy ◽  
Pharmaceutical Expenditures ◽  
Public Data ◽  
The Right ◽  
Effective Use

This article considers the pricing policy for pharmaceuticals in Australia, which is widely seen as having achieved low drug prices. However, compared to New Zealand, the evidence implies that Australia might have improved its performance significantly if it had proactively sought market best pricing. The Australian record suggests that the information sought by authorities may not be sufficient for optimal pricing and that the economic evaluation of pharmaceuticals may be neither necessary nor sufficient for achieving this goal. What is known about the topic? Pharmaceutical expenditures vary significantly across countries. Few surveys exist to determine the role of price but these suggest that Australian prices are relatively low compared with most OECD countries. What does this paper add? An analysis of public data implies that Australia pays significantly higher prices than NZ for its pharmaceuticals. This is attributable to NZ’s more effective use of competition, especially in the market for generics. Australian policy effectively limits competition by the provision of price information to competing companies. Recent agreements are similarly consistent with de facto regulatory capture. What are the implications for practitioners? There should be a review of pharmaceutical pricing policies with the criterion for success being the ‘lowest’, not ‘comparable’ world prices. Comparators should include prices paid for quality drugs in all, not selected countries, where data are available.

Generic Drugs in the Pharmaceutical Market

2016 ◽  
pp. 443-468
Author(s):  
Mercedes Rozano
Keyword(s):  
Generic Drugs ◽  
Pharmaceutical Market ◽  
National Brands ◽  
Product Categories ◽  
Pharmaceutical Expenditures ◽  
Market Shares ◽  
Generic Market ◽  
Packaged Foods ◽  
Generic Products

Over the past three decades, marketing has increased its interest in studying the role of generic products in the pharmaceutical sector, one that has only recently incorporated the concept of “generic” products, compared to others such as the mass market. Since the emergence of generic products as one of national brands' main competitors, these have shown significant growth in both their market share, as well as in new product categories. Initially, the concept of generic products was limited to categories of packaged foods and later extended to categories such as medicine. Pharmaceutical market presents an opportunity to analyze the expansion of the “generic” concept, in a strongly regulated framework. In Europe, different policies have resulted in a varying development of generic market shares. Today, the sustainability of health system is a matter of increasing concern to European governments. Generic drugs offer an opportunity to contain pharmaceutical expenditures, since generic price are lower than their original brand equivalent. Developing this market is the main objective.

Sign in / Sign up

Export Citation Format

Share Document